quinoxalines has been researched along with xl147 in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 17 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arteaga, CL; Chakrabarty, A; Kuba, MG; Rinehart, C; Sánchez, V | 1 |
| Billups, CA; Carol, H; Gorlick, R; Houghton, PJ; Kang, MH; Keir, ST; Kolb, EA; Kurmasheva, RT; Lock, R; Maris, JM; Reynolds, CP; Smith, MA | 1 |
| Baselga, J; Bedell, C; Braña, I; Edelman, G; Egile, C; Kwak, EL; Laird, AD; Nguyen, LT; Pandya, SS; Rodon, J; Scheffold, C; Shapiro, GI; Xu, Y | 1 |
| Ahmed, O; Cohen, EE; Kuo, WL; Lingen, MW; Liu, J; Macleod, KF; Nagilla, M; Sharifi, MN | 1 |
| Backes, F; Birrer, M; Campana, F; Egile, C; Ghamande, S; Martin, LP; Matulonis, U; McMeekin, S; Vergote, I; Xu, Y | 1 |
| Burris, H; Campana, F; Ciruelos, E; Garcia, AA; Gartner, E; Jiang, J; Krop, I; Maurer, M; Mayer, IA; Saura, C; Tolaney, S; Winer, E; Wu, B; Xu, Y | 1 |
| Abulafia, W; Bentzien, F; Chen, J; Chu, F; Dale, S; Du, X; Engell, K; Foster, P; Hsu, PP; Jaeger, CT; Keast, P; Laird, AD; Lam, ST; Lamb, P; Marlowe, CK; Matthews, DJ; Plonowski, A; Qian, F; Won, KA; Wu, J; Yakes, FM; Yamaguchi, K; Young, J; Yturralde, O; Yu, P; Zhang, W | 1 |
| Bahleda, R; Burris, H; Jiang, J; Lager, J; Liu, L; LoRusso, P; Macé, S; Martini, JF; Soria, JC | 1 |
| Abrisqueta, P; Awan, FT; Brown, JR; Davids, MS; Egile, C; Jiang, J; Kasar, SN; Lager, J; Rodon, J | 1 |
| Colapietro, A; Festuccia, C; Gravina, GL; Jitariuc, A; Mancini, A; Marampon, F; Ricevuto, E; Scarsella, L; Vitale, F | 1 |
| Araki, N; Hayashida, Y; Ikeda, Y; Kakehi, Y; Kato, T; Kawai, K; Sawada, K | 1 |
| Bechter, OE; Costermans, J; Dedieu, JF; Dumez, H; Francesconi, E; Ghuysen, AF; Hsu, K; Liu, L; Punie, K; Schöffski, P; Sharma, J | 1 |
| Lubet, RA; Miller, MS; Pan, J; Szabo, E; Wang, Y; Xiong, D; You, M; Zhang, Q | 1 |
| Castell, C; Jiang, J; Lager, J; Liu, L; Mutch, D; Traynor, AM; Wheler, J | 1 |
| Feng, G; Guo, X; Long, Z; Tang, L; Yu, M; Zhao, N | 1 |
| Castell, C; Edelman, G; Jiang, J; Lager, J; Lindeman, NI; Rodon, J; Shapiro, GI; Sholl, LM; Van Allen, EM; Wagle, N | 1 |
| Cook, RS; Esbona, K; Jeffery, JJ; Karim, MR; Sharick, JT; Skala, MC; Walsh, CM | 1 |
8 trial(s) available for quinoxalines and xl147
| Article | Year |
|---|---|
Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Signal Transduction; Skin Diseases; Sulfonamides; Treatment Outcome | 2014 |
Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinoxalines; Sulfonamides | 2015 |
Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Receptor, ErbB-2; Sulfonamides; Trastuzumab | 2015 |
Phase I dose-escalation study of pilaralisib (SAR245408, XL147), a pan-class I PI3K inhibitor, in combination with erlotinib in patients with solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Quinoxalines; Sulfonamides; Treatment Outcome | 2015 |
Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Sulfonamides | 2015 |
Phase I safety and pharmacokinetic dose-escalation study of pilaralisib polymorph E, a phosphoinositide 3-kinase inhibitor in tablet formulation, in patients with solid tumors or lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capsules; Dose-Response Relationship, Drug; Female; Humans; Lymphoma; Male; Middle Aged; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Sulfonamides; Tablets | 2016 |
Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinoxalines; Sulfonamides | 2017 |
Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Humans; Middle Aged; Neoplasm Staging; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinoxalines; Safety; Sulfonamides; Tablets; Treatment Outcome | 2018 |
9 other study(ies) available for quinoxalines and xl147
| Article | Year |
|---|---|
Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Screening Assays, Antitumor; Feedback, Physiological; Forkhead Transcription Factors; Gene Knockdown Techniques; Humans; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Quinoxalines; Receptor, ErbB-2; Receptor, ErbB-3; Sulfonamides; Transcription, Genetic; Up-Regulation | 2012 |
Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, Nude; Neoplasm Transplantation; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Sulfonamides; Xenograft Model Antitumor Assays | 2013 |
p62/SQSTM1 accumulation in squamous cell carcinoma of head and neck predicts sensitivity to phosphatidylinositol 3-kinase pathway inhibitors.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Autophagy; Autophagy-Related Protein 7; Carcinoma, Squamous Cell; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Gene Expression; Heterocyclic Compounds, 3-Ring; Humans; Mouth Neoplasms; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinoxalines; Sequestosome-1 Protein; Sulfonamides; Tissue Array Analysis; Ubiquitin-Activating Enzymes | 2014 |
The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Humans; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinoxalines; Ribosomal Protein S6 Kinases; Signal Transduction; Sulfonamides; Xenograft Model Antitumor Assays | 2015 |
Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Forkhead Box Protein O1; Glycogen Synthase Kinase 3 beta; Humans; Inhibitory Concentration 50; Male; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms; Quinoxalines; Receptors, Androgen; RNA, Small Interfering; Sirolimus; Sulfonamides; TOR Serine-Threonine Kinases | 2016 |
Invention of a novel photodynamic therapy for tumors using a photosensitizing PI3K inhibitor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Chromones; Dose-Response Relationship, Drug; Humans; Light; Macrophages; Mice; Molecular Imaging; Morpholines; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Photochemotherapy; Photosensitizing Agents; Quinoxalines; Reactive Oxygen Species; Sulfonamides | 2016 |
Bronchial airway gene expression signatures in mouse lung squamous cell carcinoma and their modulation by cancer chemopreventive agents.
Topics: Animals; Biomarkers, Tumor; Bronchi; Carcinoma, Squamous Cell; Chemokines, CXC; Chemoprevention; Disease Models, Animal; Gene Expression Profiling; Lung Neoplasms; Mice; Pioglitazone; Precancerous Conditions; Quinoxalines; Sulfonamides; Thiazolidinediones; Transcriptome | 2017 |
NES1/KLK10 promotes trastuzumab resistance via activation of PI3K/AKT signaling pathway in gastric cancer.
Topics: Animals; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Kallikreins; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinoxalines; Signal Transduction; Stomach Neoplasms; Sulfonamides; Trastuzumab | 2018 |
Cellular Metabolic Heterogeneity In Vivo Is Recapitulated in Tumor Organoids.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Female; Humans; Mice; Optical Imaging; Organoids; Quinoxalines; Single-Cell Analysis; Sulfonamides; Tumor Microenvironment | 2019 |